4/24
09:51 am
insm
Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models [Yahoo! Finance]
Low
Report
Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models [Yahoo! Finance]
4/24
09:33 am
insm
How The Insmed (INSM) Investment Story Is Shifting On Brinsupri And ENCORE Developments [Yahoo! Finance]
Medium
Report
How The Insmed (INSM) Investment Story Is Shifting On Brinsupri And ENCORE Developments [Yahoo! Finance]
4/23
07:00 am
insm
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
Low
Report
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
4/17
02:18 pm
insm
Insmed (INSM) had its "buy" rating reaffirmed by Roth Mkm. They now have a $212.00 price target on the stock.
Low
Report
Insmed (INSM) had its "buy" rating reaffirmed by Roth Mkm. They now have a $212.00 price target on the stock.
4/16
07:15 am
insm
Insmed (INSM) had its "buy" rating reaffirmed by Guggenheim.
Low
Report
Insmed (INSM) had its "buy" rating reaffirmed by Guggenheim.
4/14
08:57 am
insm
Insmed (INSM) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
Insmed (INSM) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
4/11
05:32 am
insm
Insmed (INSM) was upgraded by Raymond James Financial, Inc. to "moderate buy".
Low
Report
Insmed (INSM) was upgraded by Raymond James Financial, Inc. to "moderate buy".
4/10
09:00 am
insm
Insmed (INSM) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $200.00 price target on the stock.
Medium
Report
Insmed (INSM) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $200.00 price target on the stock.
4/8
07:11 am
insm
Insmed freezes Brinsupri's HS programme on Phase II failure [Yahoo! Finance]
Low
Report
Insmed freezes Brinsupri's HS programme on Phase II failure [Yahoo! Finance]
4/7
04:53 pm
insm
Insmed discontinues development of skin condition drug after mid-stage study miss [Yahoo! Finance]
Low
Report
Insmed discontinues development of skin condition drug after mid-stage study miss [Yahoo! Finance]
4/7
04:01 pm
insm
Insmed Provides Clinical Update on Phase 2b CEDAR Study
Low
Report
Insmed Provides Clinical Update on Phase 2b CEDAR Study
4/3
05:21 am
insm
Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use [Yahoo! Finance]
Low
Report
Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use [Yahoo! Finance]
4/1
02:31 pm
insm
Insmed (INSM) had its price target raised by Barclays PLC from $231.00 to $237.00. They now have an "overweight" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by Barclays PLC from $231.00 to $237.00. They now have an "overweight" rating on the stock.
3/31
02:05 am
insm
Drugmakers delay some European launches with a wary eye on Trump's pricing policies 1 / 2 [Yahoo! Finance Canada]
Medium
Report
Drugmakers delay some European launches with a wary eye on Trump's pricing policies 1 / 2 [Yahoo! Finance Canada]
3/30
09:44 pm
insm
Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28% [Yahoo! Finance]
Medium
Report
Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28% [Yahoo! Finance]
3/30
08:43 am
insm
Insmed (INSM) was upgraded by Morgan Stanley from "equal weight" to "overweight". They now have a $212.00 price target on the stock.
Low
Report
Insmed (INSM) was upgraded by Morgan Stanley from "equal weight" to "overweight". They now have a $212.00 price target on the stock.
3/26
08:17 pm
insm
Columbia Select Large Cap Growth Fund Q4 2025 Commentary [Seeking Alpha]
Low
Report
Columbia Select Large Cap Growth Fund Q4 2025 Commentary [Seeking Alpha]
3/26
12:51 pm
insm
Insmed (INSM) had its price target raised by HC Wainwright from $230.00 to $245.00. They now have a "buy" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by HC Wainwright from $230.00 to $245.00. They now have a "buy" rating on the stock.
3/25
10:56 am
insm
Insmed (INSM) had its price target raised by Mizuho from $204.00 to $206.00. They now have an "outperform" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by Mizuho from $204.00 to $206.00. They now have an "outperform" rating on the stock.
3/24
05:15 pm
insm
Insmed: "Strong Buy" As Possible Label Expansion For ARIKAYCE Bodes Well [Seeking Alpha]
Medium
Report
Insmed: "Strong Buy" As Possible Label Expansion For ARIKAYCE Bodes Well [Seeking Alpha]
3/24
11:48 am
insm
Insmed (INSM) had its price target raised by Leerink Partners from $210.00 to $215.00. They now have an "outperform" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by Leerink Partners from $210.00 to $215.00. They now have an "outperform" rating on the stock.
3/24
09:50 am
insm
Insmed (INSM) had its price target raised by Stifel Nicolaus from $205.00 to $208.00. They now have a "buy" rating on the stock.
Low
Report
Insmed (INSM) had its price target raised by Stifel Nicolaus from $205.00 to $208.00. They now have a "buy" rating on the stock.
3/24
08:42 am
insm
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success [Yahoo! Finance]
Medium
Report
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success [Yahoo! Finance]
3/24
08:30 am
insm
Insmed (INSM) had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a "buy" rating on the stock.
Medium
Report
Insmed (INSM) had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a "buy" rating on the stock.
3/23
09:35 pm
insm
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data [Yahoo! Finance]
Medium
Report
A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data [Yahoo! Finance]